Group 1 - The stock of Brainstorm Cell Therapeutics (06681) reached a new high of 13.8 HKD since its listing, but later saw a decline of over 14%, with an overall trading range of 32% throughout the day [1] - The stock had previously increased for four consecutive trading days, resulting in a cumulative rise of 125% [1] - As of the report, the stock was down 14.84%, trading at 10.04 HKD, with a total transaction volume of 1.724 billion HKD [1] Group 2 - Starting from September 8, Brainstorm Cell Therapeutics was officially included in the Hong Kong Stock Connect list, attracting southbound capital for stock accumulation [1] - By September 12, northbound investors held 2.1124 million shares, accounting for 1.66% of the total shares [1] - The company is the first in China to develop a medical-grade digital therapy product targeting cognitive impairment, with its core product being the first in the country to receive regulatory approval (registered in September 2018) [1] Group 3 - In the first half of this year, the company reported revenue of 100 million HKD, representing a year-on-year increase of 92.82% [1] - The adjusted net loss for the same period was 88.022 million HKD, which is an increase of 11.64% year-on-year [1]

Core Viewpoint - The stock of Brainstorm Cell Therapeutics (06681) experienced a dramatic surge, rising over 83% to reach a new high of 13.78 HKD, driven by its inclusion in the Hong Kong Stock Connect and the scarcity of its position as the first domestic company focused on digital therapies for cognitive disorders [1][2]. Group 1: Stock Performance Metrics - From September 8 to September 15, the stock exhibited an impressive increase of 88.91%, with a volatility of 158.23% and a turnover rate of 30.107%, resulting in a total trading volume of 35.4 billion HKD [2][3]. - The highest price reached was 13.78 HKD, while the lowest was 5.22 HKD, with a total volume of 3.812 billion shares traded during this period [3]. Group 2: Market Dynamics - The significant turnover rate of 30.107% indicates a major shift in the shareholder structure, with nearly one-third of the floating shares changing hands, suggesting a complete overhaul of the previous holding patterns [3]. - The average holding cost for the market has risen to 9.286 HKD, establishing a solid support level for future price movements [3]. Group 3: Trading Behavior Analysis - The K-line patterns revealed a complex interplay between bulls and bears, with four days of price increases but only three days showing positive closing prices, indicating a fierce battle between buying and selling pressures [4][6]. - Despite the apparent selling pressure, the volume of buying (3.572 billion shares) was significantly higher than selling (0.24 billion shares), demonstrating strong underlying demand [7]. Group 4: Investor Composition - Data shows that southbound funds were the primary drivers of this rally, with nearly 944.3 million shares acquired through the Hong Kong Stock Connect within just five days, representing 0.7458% of the total issued shares [8][10]. - In contrast, local brokers like Yao Cai Securities and Bank of China (Hong Kong) showed much smaller increases in holdings, indicating that their activities were more of a follow-up to the main buying momentum [10]. Group 5: Future Outlook - As of September 15, the stock was trading at 10.22 HKD, reflecting a 36.27% increase for the day, with a trading volume of 21.43 billion HKD, suggesting a transition into a new phase of market activity [11]. - The market is currently in a high-level consolidation phase after a rapid price increase, with future price stability dependent on continued inflows from southbound funds and the company's ability to validate its growth potential [11].

Core Viewpoint - The stock of Brainstorm Cell Therapeutics (06681) experienced a dramatic surge, rising over 83% to reach a new high of 13.78 HKD, driven by its inclusion in the Hong Kong Stock Connect and the scarcity of its position as the first domestic company focused on digital therapies for cognitive disorders [1][2]. Group 1: Stock Performance and Market Dynamics - From September 8 to September 15, the stock exhibited an impressive increase of 88.91%, with a volatility of 158.23% and a turnover rate of 30.107%, resulting in a total trading volume of 35.4 billion HKD [1][2]. - The turnover rate of 30.107% indicates a significant shift in shareholding structure, with nearly one-third of the floating shares changing hands, suggesting a complete overhaul of the previous holding patterns [2]. - The average holding cost for the market has risen to 9.286 HKD, establishing a solid support line for future price movements [2]. Group 2: Market Sentiment and Trading Behavior - The K-line pattern during this period showed a paradox where the stock rose for four days but only recorded three bullish candles, indicating a fierce battle between bulls and bears [3][5]. - Despite the apparent selling pressure, the volume of buying was significantly higher, with bullish volume at 3.572 billion shares, which is 14.88 times the bearish volume, indicating strong buying interest [6]. Group 3: Investor Composition and Market Drivers - Southbound funds were identified as the primary drivers of this rally, with nearly 944.3 million shares acquired through the Stock Connect channels within just five days, representing 0.7458% of the total issued shares [7][9]. - In contrast, local brokers like Yao Cai Securities and Bank of China (Hong Kong) showed much smaller increases in holdings, indicating that their activities were more of a follow-up to the main buying momentum [9]. Group 4: Future Outlook - The stock is currently in a high volatility phase following a significant price increase, with ongoing battles between buyers and sellers in the 10.00-11.00 HKD range [10]. - The future price stability will depend on two key factors: the continued inflow of southbound funds and the company's ability to validate its high growth potential to match the new valuation [10].

Group 1 - The market perceives that companies listed on the Hong Kong stock market benefit from being included in the Hong Kong Stock Connect, as it attracts southbound capital and enhances company visibility [1] - Brain动极光-B (06681.HK) experienced a significant price increase, rising by 32% last Friday and peaking at over 80% before a notable pullback, ultimately trading at HKD 10.4, reflecting a nearly 40% increase [1] - Since entering the Hong Kong Stock Connect, Brain动极光-B has seen its stock price nearly double, with a peak increase exceeding 100% within a week [1] Group 2 - Brain动极光 is the first Chinese company to combine brain science with advanced artificial intelligence to develop medical-grade digital therapy products for cognitive impairments [3] - The company's product pipeline addresses a wide range of cognitive impairments caused by vascular diseases, neurodegenerative diseases, mental disorders, and developmental defects in children [3] - In the first half of this year, Brain动极光 reported revenue of RMB 100 million, marking a year-on-year growth of 92.82% [3] Group 3 - Other stocks that entered the Hong Kong Stock Connect on September 8 also experienced significant price increases, such as药捷安康-B (02617.HK) with a cumulative rise of over 220% and映恩生物-B (09606.HK) with a cumulative rise of over 30% [3]

Core Viewpoint - Brainstorming Aurora-B (06681) experienced a significant stock price increase, reaching a new high since its listing, following its inclusion in the Hong Kong Stock Connect program [1] Group 1: Stock Performance - The stock surged over 83% in early trading, peaking at 13.78 HKD, marking a cumulative increase of 1.3 times since its market entry [1] - As of the report, the stock was up 61.73%, trading at 12.13 HKD with a transaction volume of 1.054 billion HKD [1] Group 2: Company Developments - Starting from September 8, Brainstorming Aurora was officially included in the Hong Kong Stock Connect list [1] - The company is recognized as the first in China to develop medical-grade digital therapy products targeting cognitive disorders, with its core product being the first to receive regulatory approval in this category (registered in September 2018) [1] - On September 12, the company announced via its official WeChat account that its series of products received the Beijing New Technology, New Product, and New Service Certificate [1] Group 3: Product Features - The products focus on intelligent assessment and precise intervention, boasting several advantages: reliance on large sample norms for accurate evaluation, multi-modal refined assessment to enhance intervention effectiveness, and an intelligent digital diagnosis and treatment platform that overcomes situational limitations [1]

Core Viewpoint - Brain动极光-B (06681) has seen a significant stock price increase, rising over 83% to a new high of 13.78 HKD since its listing, with a cumulative increase of 1.3 times since its debut [1] Group 1: Stock Performance - As of the latest update, the stock price has increased by 61.73%, trading at 12.13 HKD with a transaction volume of 1.054 billion HKD [1] - The stock was officially included in the Hong Kong Stock Connect list starting September 8 [1] Group 2: Company Overview - Brain动极光 is the first domestic company to develop medical-grade digital therapy products targeting cognitive disorders [1] - Its core product is the first cognitive disorder digital therapy product in China to receive regulatory approval, obtaining its first registration certificate in September 2018 [1] Group 3: Product Features - The company's products have recently received the Beijing New Technology, New Product, and New Service Certificate [1] - The products focus on intelligent assessment and precise intervention, featuring advantages such as precise evaluation based on large sample norms, multi-modal refined assessment to enhance intervention effectiveness, and an intelligent digital diagnosis and treatment platform that overcomes situational limitations [1]

Group 1 - The company's revenue increased from RMB 51.89 million to RMB 100.05 million for the six months ending June 30, 2025, representing a year-on-year growth of 92.81% [1] - Gross profit rose to RMB 40.85 million, a year-on-year increase of 66.60%, primarily due to a significant increase in system sales and the number of hospitals and patients using the systems [1] - Research and development expenses increased from RMB 64.23 million to RMB 68.15 million, reflecting a year-on-year growth of 6.10% [1] Group 2 - The company has established a broad pipeline of digital therapy products, with core products commercialized for eight indications across four major types of cognitive disorders [2] - The company plans to implement strategies to drive future growth, including expanding system indications, accelerating commercialization, enhancing R&D capabilities, exploring international markets, and seeking strategic acquisition opportunities [2] - The company has helped over 200 hospitals in China establish cognitive centers, including leading hospitals certified as "National Medical Centers" by the National Health Commission [1][2]

Core Insights - The 2025 Digital Therapy Conference was held in Haikou from August 15 to 16, focusing on establishing Hainan as a global hub for digital therapy innovation [1] - The conference attracted representatives from government, academia, clinical experts, and industry leaders to discuss the development direction, trends, and collaboration opportunities in digital therapy [1] Industry Overview - Digital therapy is recognized as a key direction for innovation in modern service industries and high-tech sectors, aligning with Hainan's health industry layout within the free trade port [1] - Hainan is leveraging its free trade port policy advantages to systematically promote the development of a collaborative digital healthcare ecosystem [1] Key Developments - The conference released the "Digital Medical Regional Demonstration Application Panorama," which systematically outlines typical demonstration cases across various regions, departments, and indications in China [1] - The event featured a dedicated exhibition area showcasing the "Hainan Digital Therapy Innovation Island Ecosystem," presenting a comprehensive view of digital therapy development from policy, industry, clinical implementation, and user benefits perspectives [1]

Core Points - The National Medical Products Administration (NMPA) of China released the "Guiding Principles for the Classification and Definition of Rehabilitation Digital Therapeutic Software Products," marking the first formal regulatory policy specifically targeting digital therapeutics in the country [1][8] - The guiding principles define the scope, management attributes, and classification criteria for rehabilitation digital therapeutics, establishing a significant milestone for the industry [4][8] Group 1: Definition and Characteristics - The guiding principles reference ISO/TR 11147:2023 to define digital therapeutics as health software that provides significant positive therapeutic impacts on patient health, aimed at treating or alleviating diseases or disorders [5][6] - Rehabilitation digital therapeutics are defined as software products that utilize digital technology to alleviate functional impairments or restore lost functions, with core functions including rehabilitation training and auxiliary functions such as prevention, assessment, screening, and diagnosis [5][6] - The principles outline three essential characteristics for rehabilitation digital therapeutics: software-driven interventions for functional impairments, clear clinical intended use and limitations, and adherence to evidence-based medical practices [6][7] Group 2: Regulatory Framework - The guiding principles classify rehabilitation digital therapeutics under Class II medical devices, with exceptions for products using artificial intelligence or those intended for use with assistive devices [7][8] - Prior to the release of these principles, multiple discussions and workshops were held to explore regulatory policies for digital therapeutics, indicating a long-standing need for formal guidelines [7][8] Group 3: Industry Impact and Future Expectations - The industry views the release of the guiding principles positively, as it establishes a standardized framework for the development and acceptance of rehabilitation digital therapeutics [9][10] - Experts believe that the principles will enhance the recognition and acceptance of rehabilitation digital therapeutics within clinical and industrial contexts, paving the way for better integration into healthcare systems [9][10] - The principles do not cover all digital therapeutics but specifically focus on rehabilitation, suggesting that further regulatory policies for other types of digital therapeutics may follow [12][13]

Core Viewpoint - Tencent's cognitive training software "Tencent Brain Exercise" has received medical device registration approval from the Guangdong Provincial Drug Administration, marking its entry into clinical application for improving cognitive abilities in patients with mild cognitive impairment (MCI) [1][3] Industry Overview - The cognitive digital therapy market in China has over 40 companies focusing on this area, with 47 cognitive digital therapy software products approved by the National Medical Products Administration as of October 2024 [2] - The market for cognitive impairment digital therapy is expected to grow significantly, with a projected market size of 2.686 billion yuan in 2023, increasing to 10.467 billion yuan by 2025 and 89.274 billion yuan by 2030, reflecting compound annual growth rates of 97.4% and 53.5% respectively [4] - The number of MCI patients in China is approximately 38.77 million, with a prevalence rate of 15.5%, indicating a substantial patient base driving demand for cognitive digital therapies [4] Company Insights - Tencent's "Tencent Brain Exercise" transforms traditional cognitive rehabilitation into a mobile application format, utilizing gamified cognitive training based on evidence-based medicine principles [3] - The company aims to address the challenges of commercializing digital therapies, as the current business models are still in the early stages of development [1][2] - Brain Dynamics, a competitor in the market, has achieved a market share of 25.0% in the cognitive digital therapy market and 91.6% in the medical-grade cognitive digital therapy market in China, but faces challenges in profitability despite significant revenue growth [5] Challenges in the Market - The cognitive digital therapy sector is experiencing high market education costs and is still in the exploratory phase regarding application scenarios [1][2] - Regulatory challenges exist, as clinical experts have varying opinions on the clinical use of digital therapy products, which complicates their appropriate application [4][5] - The industry faces difficulties in ensuring that payers (such as insurance companies and hospitals) are willing to cover these therapies, which is crucial for sustainable business models [1][2] Competitive Landscape - Major tech companies like Tencent, Alibaba, and ByteDance are entering the healthcare sector, but a mature commercialization model is still needed [6] - The cognitive digital therapy market is characterized by a mix of substantial patient demand and ongoing challenges in commercialization pathways, creating a complex development landscape [2][4]